SCHEMBL27244147

SCHEMBL27244147

COC(=O)c1cc2c(N=CN(C)C)nn(-c3ccccc3)c2s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.64
ALDH1A1 P00352 7/20 0.64
HPGD P15428 6/20 0.64
HSD17B10 Q99714 5/20 0.64
POLB P06746 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.51
MAPT P10636 6/20 0.46
ESR1 P03372 1/20 0.46
RNASEL Q05823 1/20 0.44
TSHR P16473 1/20 0.44
NPC1 O15118 2/20 0.44
TP53 P04637 1/20 0.44
PKM P14618 1/20 0.44
HTT P42858 2/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SAE1 Q9UBE0 1/20 0.43
UBA2 Q9UBT2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27251818 1.00 KDM4E (0.64) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL27244157 0.91 KDM4E (0.61) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL27244151 0.91 KDM4E (0.61) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL27244031 0.78 KDM4E (0.76) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL27244153 0.71 KDM4E (0.40) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL27243734 0.71 KDM4E (0.64) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL853240 0.68 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL854276 0.68 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL27243907 0.68 KDM4E (0.82) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL854234 0.66 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598923-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS The Regents of the University of California (US) 2025-08-13 EP disclosed
US-20240201205-A1 METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
US-20240197682-A1 METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
WO-2024059845-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS MAPT, HTT, PSEN1 KDM4E 4298/4885ALDH1A1 4342/4885HPGD 3107/4885
US-20240197682-A1 METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS PRNP, PSEN1, SNCA KDM4E 4814/4885ALDH1A1 4385/4885HPGD 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.